2012 Competition Leads 
European Pharmaceutical Review
DECEMBER 14, 2023
Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 Lane S, Lynn E, Shakir S.
CloserIQ
OCTOBER 10, 2018
Founded 2012. Founded 2012. They’ve worked with leading clients such as Twitter and Mercedes Benz. Founded 2012. Founded 2012. Founded 2012. They are seeking to transform the automobile industry and are known for a fast-paced, collaborative work environment. ProfitWell. 11-50 employees. $10 See open roles.
pharmaphorum
JANUARY 5, 2023
The drive to make the UK a ‘scientific powerhouse’ was central to the government’s announcement closing out 2022 , which appointed five industry experts to lead on the sectors most vital to UK’s future innovation. Since co-founding Benchling in 2012, Ashu has overseen the company’s rapid growth. About the author.
European Pharmaceutical Review
JULY 4, 2024
2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).
pharmaphorum
JULY 27, 2022
Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.
European Pharmaceutical Review
AUGUST 23, 2022
Article 15 proved that transparent and effective assessments of new technologies were crucial to ensure fair competition between stakeholders that operate in the EU. In addition, he was Head of the Legal Service at the European Medicines Agency from 2004 to 2012. effectiveness and therapeutic efficacy.
European Pharmaceutical Review
DECEMBER 22, 2022
In recent years significant improvements in automation of cell line development have reduced timelines for demonstrating productivity and clonality of lead cell lines from months to weeks. Using this data, it was possible to select a lead cell line that was scalable and produced 8 g/l across 15ml to 200l (see Figure 2 ).
Expert insights. Personalized for you.
116 
Let's personalize your content